GO
Loading...

Enter multiple symbols separated by commas

Teva Pharmaceutical Industries Ltd

More

  • Teva discloses 1.35 pct stake in target Mylan Wednesday, 27 May 2015 | 4:42 PM ET

    May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...

  • TRENTON, N.J.— Drugmaker Endo International PLC is climbing toward the top of the steadily consolidating generic medicine business with a deal to buy Par Pharmaceutical Holdings Inc. for about $8.05 billion. In the U.S., that includes the biggest health insurers and two pharmacy benefit managers, Express Scripts Holding Co. and CVS Health Corp. In other...

  • May 8- A U.S. judge on Friday dismissed a lawsuit filed by the city of Chicago in federal court against four drugmakers accused of promoting painkiller addiction through deceptive marketing, though the case will continue against Oxycontin maker Purdue Pharma LP. The companies dismissed from the lawsuit are Teva Pharmaceutical Industries Ltd, Johnson&...

  • May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The case, which began in 2000 in California state court, centers on a series of settlements in the late 1990 s under...

  • Top California court revives Cipro antitrust case Thursday, 7 May 2015 | 1:12 PM ET

    May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The ruling marks the first time an appellate court has tackled so-called "pay for delay" deals since a landmark...

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • Early movers: GEVA, MGI, JPM, WEN, NWSA & more Wednesday, 6 May 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co.. "We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion," Mylan Chief Executive...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland- based Perrigo Co.. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend...

  • U.S. top court rejects hepatitis B drug patent case Monday, 4 May 2015 | 9:40 AM ET

    WASHINGTON, May 4- The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the...

  • Biotech bust may be sending message about stocks Thursday, 30 Apr 2015 | 5:03 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries raised its 2015 earnings forecast after beating first-quarter estimates, and said it would devote "all necessary resources" to its $40 billion- plus bid for rival Mylan Inc..

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower as investors weighed earnings and looked ahead to the beginning of the two-day Federal Reserve meeting on Tuesday.

  • What's wrong with healthcare and biotech? Monday, 27 Apr 2015 | 3:32 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.